📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future 👉close surveillance ➡️ early detection of iRAEs➡️ early treatment➡️ reversibility or ⬇️severity #ACRAmbassador https://t.co/AM2mfYmAtI

"The goal of a vaccine is not just to protect a (vaccinated) individual, but to end the pandemic." Dr. Dan Barouch #ACR20 @RheumNow

Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?

Just watched David Beck’s talk on somatic mutations in VEXAS. Genotyping to link phenotypically diverse disease. Such an exciting strategy to identify additional unknown diseases!!! #ACR https://t.co/gU9HEZyjRP

Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis patients taking #JAKinhibitors - Most RA pts on JAKi have sufficient antibody response to HZ vaccine - Acceptable safety profile Abs#1997 #ACR20 @RheumNow https://t.co/8HWAIwOATD

• Immunogenicity of Adjuvanted Herpes Zoster Subunit Vaccine in Rheumatoid Arthri…

Just a reminder: inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced. @LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/qdEpNpzdNs

Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/UlDe4NllU0

Dr Winthrop reports on rates of influenza in RA in tofactinib clinical programme over 14-15 seasons. No significant differences in rates between tofa, ADA, MTX, and placebo. @rheumnow #ACR20 Abstr#L04 https://t.co/8RrG0I2Zwm